Evidence map›Paper›PMID 38974817›Full record

Observational studyInternational journal of chronic obstructive pulmonary disease2024

Expiratory Venous Volume and Arterial Tortuosity are Associated with Disease Severity and Mortality Risk in Patients with COPD: Results from COSYCONET.

Mircea Gabriel Stoleriu, Michael Pienn, Rudolf A Joerres, Peter Alter, Tamas Fero, Martin Urschler, Gabor Kovacs, Horst Olschewski, Hans-Ulrich Kauczor, Mark Wielpütz and 10 more

Registry-linked trialAbstract readMulticenter StudyObservational Study
In one paragraph

Observational study in International journal of chronic obstructive pulmonary disease, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01245933 (Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01245933 completednot on this map

Impact of Systemic Manifestations/Comorbidities on Clinical State, Prognosis and Utilisation of Health Care Resources in Patients With COPD

TypeobservationalSponsorPhilipps University MarburgRan2010 to 2023Enrolled2,741ConditionsChronic Obstructive Pulmonary Disease (COPD)
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Vascular remodeling in asthma: from mechanisms to precision medicine.Current opinion in allergy and clinical immunology · 2026
    Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mircea Gabriel Stoleriu *Division for Thoracic Surgery Munich, Ludwig-Maximilians-University of Munich (LMU) and Asklepios Medical Center; Munich-Gauting, Gauting, 82131, Germany.ORCID 0000-0002-1288-809X
Michael Pienn *Ludwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.ORCID 0000-0001-5542-7069
Rudolf A JoerresInstitute and Outpatient Clinic for Occupational, Social and Environmental Medicine, Hospital of Ludwig-Maximilians-University Munich (LMU), Munich, 80336, Germany.ORCID 0000-0002-9782-1117
Peter AlterDepartment of Medicine, Pulmonary and Critical Care Medicine, University of Marburg (UMR), Member of the German Center for Lung Research (DZL), Marburg, 35033, Germany.ORCID 0000-0002-2115-1743
Tamas FeroDepartment of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
Martin UrschlerInstitute for Medical Informatics, Statistics and Documentation, Medical University of Graz, Graz, Austria.ORCID 0000-0001-5792-3971
Gabor KovacsLudwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.
Horst OlschewskiLudwig Boltzmann Institute for Lung Vascular Research, Graz, Austria.ORCID 0000-0002-2834-7466
Hans-Ulrich KauczorDepartment of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
Mark WielpützDepartment of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
Bertram JobstDepartment of Diagnostic and Interventional Radiology, University Hospital Heidelberg, Heidelberg, Germany.
Tobias WelteDepartment of Respiratory Medicine and Infectious Disease, Member of the German Center of Lung Research, Hannover School of Medicine, Hannover, Germany.ORCID 0000-0002-9947-7356
Jürgen BehrInstitute for Lung Health and Immunity and Comprehensive Pneumology Center with the CPC-M bioArchive; Helmholtz Center Munich; Member of the German Lung Research Center (DZL), Munich, 81377, Germany.
Franziska C TrudzinskiTranslational Lung Research Center Heidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany.ORCID 0000-0002-0980-7586
Robert BalsDepartment of Internal Medicine V-Pulmonology, Allergology and Respiratory Critical Care Medicine, Saarland University, Homburg, 66421, Germany.
Henrik WatzPulmonary Research Institute at LungenClinic Grosshansdorf, Airway Research Centre North, German Centre for Lung Research, Großhansdorf, Germany.
Claus F VogelmeierDepartment of Medicine, Pulmonary and Critical Care Medicine, University of Marburg (UMR), Member of the German Center for Lung Research (DZL), Marburg, 35033, Germany.
Jürgen Biederer *Translational Lung Research Center Heidelberg, Member of the German Center for Lung Research DZL, Heidelberg, Germany.
Kathrin Kahnert *Institute for Lung Health and Immunity and Comprehensive Pneumology Center with the CPC-M bioArchive; Helmholtz Center Munich; Member of the German Lung Research Center (DZL), Munich, 81377, Germany.
COSYCONET Study Group

Funding

Boehringer Ingelheim Pharma GmbH & Co. KG, Chiesi GmbH, GlaxoSmithKline, Grifols Deutschland GmbHCompetence Network Asthma and COPD (ASCONET)German Center for Lung Research (DZL)German Federal Ministry of Education and Research (BMBF)MSD Sharp & Dohme GmbH, Mundipharma GmbH, Novartis Deutschland GmbHNovartis Pharma GmbHPfizer Pharma GmbH, Takeda Pharma Vertrieb GmbH & Co. KG, Teva GmbHUnrestricted Grants from AstraZeneca GmbH, Bayer Schering Pharma AG
6 · The paper itself

Abstract

Purpose: The aim of this study was to evaluate the association between computed tomography (CT) quantitative pulmonary vessel morphology and lung function, disease severity, and mortality risk in patients with chronic obstructive pulmonary disease (COPD). Patients and Methods: Participants of the prospective nationwide COSYCONET cohort study with paired inspiratory-expiratory CT were included. Fully automatic software, developed in-house, segmented arterial and venous pulmonary vessels and quantified volume and tortuosity on inspiratory and expiratory scans. The association between vessel volume normalised to lung volume and tortuosity versus lung function (forced expiratory volume in 1 sec [FEV Results: Complete data were available from 138 patients (39% female, mean age 65 years). FEV Conclusion: By using automated software in patients with COPD, clinically relevant information on pulmonary vasculature can be extracted from expiratory CT scans (although not inspiratory scans); in particular, expiratory pulmonary venous volume predicted mortality. Trial Registration: NCT01245933.

Indexed as

LungPredictive Value of TestsPulmonary ArteryPulmonary Disease, Chronic ObstructiveSeverity of Illness IndexAgedComputed Tomography AngiographyFemaleForced Expiratory VolumeHumansLinear ModelsLogistic ModelsMaleMiddle AgedMultidetector Computed TomographyNetherlandscomputed tomographyCOPDlung functionpulmonary vasculaturevessel tortuosityvessel volume

Identifiers

PMID38974817
PMCPMC11227296

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.